PAK1 inhibitor IPA-3 mitigates metastatic prostate cancer-induced bone remodeling

Metastatic prostate cancer (PCa) has high mortality and a poor 5-year survival rate primarily due to the lack of effective treatments. Bone is the primary site of PCa metastasis in humans and the development of reliable therapeutic options for bone metastatic PCa will make a huge impact in reducing...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Biochem Pharmacol
Main Authors: Verma, Arti, Artham, Sandeep, Alwhaibi, Abdulrahman, Adil, Mir S., Cummings, Brian S., Somanath, Payaningal R.
Formato: Artigo
Idioma:Inglês
Publicado: 2020
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7414983/
https://ncbi.nlm.nih.gov/pubmed/32240651
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bcp.2020.113943
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares